There’s always a lot of anticipation about the “late breaker” session, which presents research that wasn’t available until the last mi...

Results from a clinical trial presented at the XVI International AIDS Conference (IAC) indicate that maraviroc, Pfizer’s experimental entry in...

The AIDS Clinical Trials Group has reported results from a clinical trial of vicriviroc, an experimental entry inhibitor being developed by Sc...

Preliminary results from an ongoing clinical trial of MK-0518, Merck’s experimental integrase inhibitor, suggest that it has comparable anti-H...

Forty-eight week results from a phase II clinical trial of TNX-355, an HIV-entry inhibitor, were reported today at the XVI International AIDS...

AIDSmeds Founder Peter Staley interviewed Dr. Donald Kotler, Chief of Gastroenterology at St. Luke’s-Roosevelt Hospital.

Encouraging results from a second study were reported today.

Final data from a 48-week study comparing Norvir (ritonavir)-boosted Lexiva (fosamprenavir) to Kaletra (ritonavir-boosted lopinavir).

AIDSmeds Founder Peter Staley interviewed Gregg Gonsalves, former Director of Treatment & Prevention Advocacy at GMHC.

Peter Staley interviewed Dr. Alan Tennenberg, Tibotec’s VP of Clinical Affairs, regarding the latest clinical data on Prezista.